301126.SHE Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
- Market cap
- CNY 1.78B
- P/E
- -
- P/B
- 1.19x
- ROE
- 0.9%
- Dividend yield
- 6.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301126.SHE undervalued?
Graham numberThe Graham number of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd fundamental analysis
No fundamental analysis for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd yet.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. engages in pharmaceutical manufacturing, distribution, retail, and research and development activities in China and Hong Kong. The company operates retail pharmacy services, including Direct-to-Patient specialty pharmacy operations covering medications for cancer treatment, antiviral therapies, and organ transplant procedures. It also serves as an emergency pharmaceutical storage provider and public health emergency sup…
Full company profileHunan Dajiaweikang Pharmaceutical Industry Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.46B | 2.34B | 2.59B | 3.29B | 3.90B | 5.23B | 5.14B | 5.38B |
| Gross Profit | 290M | 269M | 306M | 396M | 577M | 1.04B | 936M | 990M |
| Operating Income | 171M | 128M | 146M | 134M | 144M | 209M | 110M | 187M |
| EBITDA | 374M | 214M | 152M | 156M | 195M | 321M | 42.8M | 147M |
| Net Income | 87.7M | 64.9M | 68.3M | 51.1M | 34.3M | 26.6M | -242M | 13.0M |
| EPS | 0.57 | 0.42 | 0.33 | 0.25 | 0.17 | 0.13 | -1.18 | 0.06 |
| Balance Sheet | ||||||||
| Total Assets | 2.02B | 2.20B | 2.99B | 3.93B | 5.28B | 6.18B | 6.34B | 6.18B |
| Total Liabilities | 1.04B | 1.16B | 1.32B | 2.11B | 3.50B | 4.33B | 4.74B | 4.55B |
| Shareholders' Equity | 977M | 1.04B | 1.68B | 1.72B | 1.75B | 1.76B | 1.49B | 1.50B |
| Cash & Short-term Investments | 162M | 229M | 748M | 543M | 649M | 620M | 587M | 288M |
| Cash Flow | ||||||||
| Operating Cash Flow | 136M | -151M | -162M | -494M | 27.1M | 24.0M | -149M | - |
| Capital Expenditure | 32.5M | 45.9M | 33.3M | 209M | 227M | 187M | 105M | 44.4M |
| Free Cash Flow | 103M | -197M | -195M | -703M | -200M | -163M | -254M | -155M |
| Ratios | ||||||||
| ROE | 9.0% | 6.2% | 4.1% | 3.0% | 2.0% | 1.5% | -16.3% | 0.9% |
| ROA | 4.3% | 2.9% | 2.3% | 1.3% | 0.6% | 0.4% | -3.8% | 0.2% |
| Net Profit Margin | 3.6% | 2.8% | 2.6% | 1.6% | 0.9% | 0.5% | -4.7% | 0.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd dividends
- Dividend yield
- 6.27%
- Forward dividend
- 0.02 CNY
- Payout ratio
- -
- Ex-dividend date
- Dec 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 112M | 0.55 | - |
| 2024 | CNY 92.4M | 0.45 | 347.5% |
| 2023 | CNY 72.4M | 0.35 | 211.2% |
| 2022 | CNY 41.2M | 0.20 | 80.7% |
| 2021 | CNY 31.0M | 0.15 | 45.4% |
| 2020 | CNY 31.0M | 0.20 | 47.7% |
| 2019 | CNY 37.6M | 0.24 | 42.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
- Insiders 50.69%
- Institutions 9.54%
- Public & others 39.77%
- Shares outstanding 205M
- Free float 108M
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd company profile
- Company name
- Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
- Ticker
- 301126.SHE
- ISIN
- CNE1000054V3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 5,339
- Fiscal year end
- December
- Address
- No.30, Fuling Road, Changsha, China, 410000
- Phone
- 86 731 8451 2838
- Website
- djwk.com.cn
About Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. engages in pharmaceutical manufacturing, distribution, retail, and research and development activities in China and Hong Kong. The company operates retail pharmacy services, including Direct-to-Patient specialty pharmacy operations covering medications for cancer treatment, antiviral therapies, and organ transplant procedures. It also serves as an emergency pharmaceutical storage provider and public health emergency supply contractor for Hunan Province. Additionally, the company provides pharmaceutical services, including patient health record management, chronic disease management, and a patient data management system. It manufactures pharmaceutical products. The company also operates a pharmaceutical wholesaling and distribution business across Hunan Province. Additionally, it operates a full-time specialized medical institution, conducts pharmaceutical research and development activities, and engages in regenerative medicine operations. The company offers Chinese patent medicines, chemical pharmaceuticals, medical devices, cleansing and care products, medicinal wines, and food products. It serves hospitals, medical institutions, institutional pharmacy clients, and individual patients. TAT KA WAI HONG Pharmaceutical Industry Group Co., Ltd. was formerly known as Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. and changed its name to Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. in September 2026. Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. was founded in 2002 and is based in Changsha, China.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd management
4- Ms. Shengli HuGM, Financial Director & Director · born 1974
- Ms. Shanhu ChenDirector & Deputy GM · born 1983
- Ms. Qian JiangBoard Secretary & Director · born 1988
- Hao QinAccounting Supervisor